TABLE 4.
Results for 68Ga-DOTATATE
| Vaccinated (13 patients) | DS (3 patients) | ||||||
|---|---|---|---|---|---|---|---|
| Parameter | Total (14 patients) | Control group (1 patients) | Once (2 patients) | Twice (11 patients) | Once (1 patients) | Twice (2 patients) | Index (%) |
| Mean interval from vaccination to PET/CT (d) | NA | NA | 6 (range, 3–8) | 14 (range, 2–21) | 3 | 4 (range, 2–5) | NA |
| Lymphadenopathy | |||||||
| Patients (n) | 12 (86%) | 0 | 2 (15%) | 10 (77%) | 1 (33%) | 2 (67%) | S*, 87.5; Sp*, 100; PPV*, 100; NPV*, 50‡ |
| LN appearance | |||||||
| Benign | 12 (100%) | N/A | 2 (100%) | 10 (100%) | 3 (100%)† | ||
| Malignant | 0 | N/A | 0 | 0 | 0† | ||
| Equivocal | 0 | N/A | 0 | 0 | 0† | ||
| Size (cm) in short axis | 0.5–1.1 | N/A | 0.5–1.1† | 0.5–0.9† | |||
| SUVmax | 1–3.5 | N/A | 1–3.5† | 1.6–3.5† | |||
| Arm (patients [n]) | 3 (21%) | 0 | 3 (23%)† | 3 (100%)† | NA | ||
| 1 (33%) | 2 (67%) | 1 (33%) | 2 (67%) | ||||
| DS (patients [n]) | 3 (21%) | 0 | 3 (23%)† | —† | S, 75; Sp, 100; PPV, 100; NPV, 50 | ||
| 1 (33%) | 2 (67%) | —† | |||||
*For unilateral axillary lymphadenopathy only, with increased uptake (SUVmax > 1.0) and benign appearance.
†Applies to both once-vaccinated and twice-vaccinated patients.
‡Control group, only 1 patient.
S = sensitivity; Sp = specificity; NA = not applicable.